Tesamorelin + Ipamorelin (TESA IPA) Blend

The TESA IPA peptide blend combines Tesamorelin, a growth hormone–releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue. Working through complementary signaling routes, the pair provides an enhanced model for examining growth hormone activity in research environments.

For instance, Tesamorelin supports pituitary-level pathways by replicating natural GHRH function. In parallel, Ipamorelin interacts with ghrelin receptors to promote GH release while avoiding elevations in cortisol or prolactin. This coordinated mechanism produces a more robust GH-related response than either compound individually.

Researchers utilize the blend in studies related to metabolic regulation, lean tissue modeling, adipocyte behavior, and sleep-associated signaling patterns. Additionally, ongoing research employs this combination to explore how growth hormone influences recovery processes, energy balance, and cognitive pathways.

Lastly, TESA IPA is produced in controlled, laboratory-grade formulations to support precise experimental conditions. It is provided strictly for research and development purposes and is not intended for human use.